A meta-analysis of the long-term efficacy of Amantadine for Levodopa-induced dyskinesia in Parkinson’s disease
Our findings suggest that Amantadine is an effective adjunct medication for improving LID and broader Parkinson's disease symptoms. However, evidence of its declining long-term efficacy and "adverseness" have important implications for its use in Parkinson's disease therapy.
Authors
- Maurice A. Curtis (ORCID: https://orcid.org/0000-0003-4496-0233)
- Kayla Williams (ORCID: https://orcid.org/0009-0000-2690-8453)
- Priya Parmar (ORCID: https://orcid.org/0000-0001-6001-9326)
- Lisa Gombinsky
Institutions
- University of Auckland (NZ)
- Education New Zealand (NZ)
- Brain Research New Zealand (NZ)
Publication Details
- Journal
- Clinical Parkinsonism & Related Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.prdoa.2025.100405
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00